Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Kristine A. Frerichs(National Cancer Center), Niels W.C.J. van de Donk(Oncode Institute), Bronno van der Holt(Erasmus MC), Ajay K. Nooka(Emory University), María‐Victoria Mateos(Hospital Clínico San Carlos), Cesar Rodriguez(Wake Forest University), Diana Cortés‐Selva(Johnson & Johnson (United States)), Deeksha Vishwamitra(Janssen (United States)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Thomas G. Martin(University of California San Francisco Medical Center), Maria T. Kuipers(Amsterdam University Medical Centers), Sandy Kruyswijk(Amsterdam University Medical Centers), Alfredo Perales‐Puchalt(The Wistar Institute), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Sonja Zweegman(Vrije Universiteit Amsterdam), Margaret Doyle(Janssen (Ireland)), Katherine Chastain(Janssen (United States)), Hans L. Zaaijer(Sanquin), Sheri Skerget(Translational Genomics Research Institute), Kaz Groen(Amsterdam University Medical Centers), Christie P.M. Verkleij(Dutch Cancer Society)
Cited by 85
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Serum amyloid A, the major vertebrate acute‐phase reactant
|European Journal of Biochemistry|1999|1.1k